

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: 058823-0110 (RTS-0678US) Customer No.: 71476

Applicant: Bhanot, Sanjay Confirmation No.: 4755

Serial No.: 10/643,801 Group Art Unit: 1635

Filed: August 18, 2003 Examiner: Angell, Jon E.

Title: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2
EXPRESSION

REQUEST TO CORRECT INVENTORSHIP

Pursuant to 37 C.F.R. §1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby petition, pursuant to 37 C.F.R. §1.48(a), to have Brett P. Monia added as a named inventor to the above-identified non-provisional application.

Brett P. Monia is a citizen of the United States of America, residing in Encinitas, California, USA.

Applicants submit that the inventorship error occurred without deceptive intent on the part of the omitted inventors.

The inventors of U.S. Patent application serial number 10/643,801 should be listed as follows: Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, and Brett P. Monia.

Included herewith is a Statement from the Assignee pursuant to 37 C.F.R. §1.48(a), a Statement Confirming No Deceptive Intent on the part of the inventor, a Statement Under 37 CFR 3.73(b), an Assignment executed by the inventor, and a

Docket No.: 058823-0110(RTS-0678US)

Serial No. 10/643,801

Supplemental Application Data Sheet. Also included herewith is a Declaration pursuant to 37 C.F.R. §1.63 executed by each inventor and containing a complete listing of all inventors.

The Director is hereby authorized to charge the processing fee set forth in § 1.17(i), the assignment recordation fee, and any other fees due with the filing of this paper to the Isis Pharmaceuticals, Inc., Deposit Account 50-0252.

Respectfully submitted,

Date: 1/12/2010



Reena R. Desai, Esq.
Registration No. 53,833

Isis Pharmaceuticals, Inc
1896 Rutherford Rd.
Carlsbad, CA 92008
(760) 603-2473 – Direct
(760) 603-3820 – Facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: 058823-0110 (RTS-0678US) Customer No.: 71476
Applicant: Bhanot, Sanjay Confirmation No.: 4755
Serial No.: 10/643,801 Group Art Unit: 1635
Filed: August 18, 2003 Examiner: Angell, Jon E.
Title: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2
EXPRESSION

STATEMENT FROM ASSIGNEE


Pursuant to 37 C.F.R. §1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I hereby assert that I am authorized to act on behalf of the assignee, Isis Pharmaceuticals Inc., 1896 Rutherford Road, Carlsbad, California, 92008, the owner of the entire right, title and interest in U.S. Patent Application No. 10/643,801 (see attached Statement under 37 C.F.R. § 3.73(b)). I further hereby assert that the assignee agrees to the inventorship change in U.S. Patent Application No; 10/643,801 to the following inventive entity:

Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, and Brett P. Monia

Signed this 12th day of January, 2010 by 

Jason D. Ferrone
Vice President and Senior Patent Counsel
Isis Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008-7208

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Isis Pharmaceuticals, Inc.Application No./Patent No.: 10/643,801Filed/Issue Date: 08/18/2003Titled: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSIONIsis Pharmaceuticals, Inc, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 15031 / 23748, Frame 0790 / 0917, or for which a copy therefore is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Jason D. Ferrone, J.D.

Printed or Typed Name

12 Jan 2010

Date

Vice President and
Senior Patent Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: 058823-0110 (RTS-0678US) Customer No.: 71476
Applicant: Bhanot, Sanjay Confirmation No.: 4755
Serial No.: 10/643,801 Group Art Unit: 1635
Filed: August 18, 2003 Examiner: Angell, Jon E.
Title: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2
EXPRESSION

STATEMENT CONFIRMING NO DECEPTIVE INTENT
Pursuant to 37 C.F.R. §1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Brett P. Monia, hereby state that I am to be added as an inventor to United States Patent Application No. 10/643,801, along with fellow inventors Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, and I further state that the error in omitting me from being listed as an inventor occurred without deceptive intent on my part.

Signed this 4 day of Jan, 2010 by Brett P. Monia
Brett P. Monia